In the largest and most conclusive study of its kind, researchers have analysed blood samples to create a novel and non-invasive way of helping to diagnose Alzheimer’s disease and distinguish between different types of neurodegenerative disorders.
Following this breakthrough discovery, Alzheimer’s sufferers may now have an additional test to improve the accuracy of diagnosis in order to better tailor appropriate treatment.
The research also offers a valuable opportunity to monitor the progression of the disease.
The international study in the Proceedings of the National Academy of Sciences USA used sensor-based technology with a diamond core to analyse approximately 550 blood samples.
By passing light through the diamond and observing its interactions with the blood plasma, researchers were able to identify specific chemical bonds within the blood. This biochemical data was used to compare blood samples from cases of Alzheimer’s disease and other neurodegenerative diseases with those from healthy controls.
The ground-breaking scientific investigation was carried out by researchers at Lancaster University, the University of Central Lancashire (UCLan), the University of Manchester and the Federal University of Rio Grande do Norte, Brazil.
Professor David Allsop from Lancaster University has been collaborating for many years withProfessor David Mann from the University of Manchester in searching for diagnostic markers for neurodegenerative disease in blood plasma.
They provided all of the plasma samples for the study, along with supporting clinical and genetic information, and expertise in Alzheimer’s and other neurodegenerative conditions.
Professor Allsop said: “A particularly exciting aspect of the study was the ability to distinguish accurately between Alzheimer’s disease and Lewy body dementia, which are conditions that both result in dementia and can be difficult to separate from each other based on clinical information and symptoms. By reduction of misdiagnosed cases and administration of appropriate treatment, many people could benefit from this type of blood test in the future.”
Alzheimer’s diagnosis currently involves careful medical evaluation including clinical history, memory testing and brain scans, yet the only conclusive diagnosis is determined by post-mortem examination. This new blood test offers a non-invasive, more accurate and relatively cost-effective method of diagnosis, which will ensure the correct management of the condition.
Professor Francis Martin, principal investigator of the study and Biosciences theme lead at UCLan, said: “We have an aging population, meaning that the incidence and prevalence of Alzheimer’s is increasing, as is the need for accurate diagnosis. The ability to identify different neurodegenerative diseases through the analysis of blood offers a faster and accurate way of establishing the most effective treatment plan as well as disease monitoring.”
This new approach could also offer potential for carrying out tests to identify and monitor early signs of mild cognitive impairment, meaning that the onset of Alzheimer’s and other types of neurodegenerative diseases could be detected early and intervention measures could be put in place earlier to slow the progress of these diseases.
Professor Martin added: “For those suffering with Alzheimer’s disease, the damage is already well advanced once conventionally diagnosed, but this new method offers a potentially effective early screening tool when patients are only demonstrating signs of mild cognitive impairment. This is a potentially significant breakthrough for the prevention of different debilitating and chronic neurological diseases.”
The Latest on: Alzheimer’s
- The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer’s diseaseon August 12, 2020 at 2:09 am
Recently, the focus of Alzheimer’s disease (AD) research has shifted from the clinical stage to the preclinical stage. We, therefore, aimed to develop a cognitive composite score that can detect the ...
- Researchers discover a simpler way to diagnose Alzheimer's diseaseon August 12, 2020 at 1:18 am
The Republic of Korea, like other countries with a rapidly ageing population, is facing increasing numbers of patients with dementia, of which Alzheimer's disease (AD) is the most representative type.
- Mucus shows promise as cheap and easy diagnostic tool for Alzheimer'son August 12, 2020 at 12:26 am
With so much we are yet to understand about how Alzheimer’s develops, scientists are coming at the problem from all kinds of angles. This includes exploring the disease’s relationship with our ...
- From promising progress on blood test to impact of video chat, Alzheimer’s research persists in pandemicon August 11, 2020 at 9:43 pm
Face-to-face interaction through technology like video chat can help those dealing with social isolation during the pandemic.
- Judge Agrees to Retire After Alzheimer’s Diagnosison August 11, 2020 at 3:54 pm
Judge ShawnDya L. Simpson, 54, agreed to step down after the Commission on Judicial Conduct determined her behavior in court was “erratic and at times intemperate.” ...
- Study: Seniors can handle receiving Alzheimer's risk test resultson August 11, 2020 at 2:23 pm
As detection methods for Alzheimer's disease risk improve, mental health professionals have worried what the psychological fallout of that knowledge might be. But new research suggests that people can ...
- FDA Approves Initiation of IGC’s Cannabinoid Trial on Alzheimer’s Patientson August 11, 2020 at 2:03 pm
India Globalization Capital (“IGC” or the “Company”) (NYSE American: IGC) announced today that on July 30, 2020, the U.S. Food and Drug Administration (FDA) notified IGC that it has authorized the ...
- Study identifies protein in the blood that may predict Alzheimer’son August 11, 2020 at 9:22 am
A newly published study has found a type of protein in people’s blood that may be an early predicting sign of Alzheimer’s disease.
- TrkB receptor cleavage by delta-secretase abolishes its phosphorylation of APP, aggravating Alzheimer’s disease pathologieson August 11, 2020 at 7:57 am
Neurotrophins promote neuronal survival and synaptic plasticity via activating the tropomyosin receptor kinases. BDNF and its high-affinity receptor TrkB are reduced in Alzheimer’s disease (AD), ...
- Medicare coverage for Alzheimer’s disease scans still in questionon August 11, 2020 at 3:08 am
A big study to help Medicare officials decide whether to start covering brain scans to check for Alzheimer’s disease missed its goals for curbing health care costs, calling into question whether the ...
via Google News and Bing News